• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Ropeginterferon Alfa-2b Controls Polycythemia Vera and Cuts Phlebotomy Needs in Practice

by
November 17, 2026
in Health
Reading Time: 3 mins read
0
Ropeginterferon Alfa-2b Controls Polycythemia Vera and Cuts Phlebotomy Needs in Practice

Ropeginterferon Alfa-2b Controls Polycythemia Vera and Cuts Phlebotomy Needs in Practice

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In routine clinical practice, ropeginterferon alfa-2b provided progressive hematologic control and substantially reduced phlebotomy requirements in patients diagnosed with definitive polycythemia vera, according to a retrospective, single-center study published in Annals of Hematology. The investigation evaluated real-world outcomes outside clinical trials to address limited existing evidence regarding hematologic effectiveness, treatment modifications, tolerability, and treatment discontinuation among consecutive patients receiving ropeginterferon alfa-2b therapy.

The single-center study cohort included 42 consecutive treated patients who were all incorporated into the primary safety analyses. However, assessments of treatment effectiveness and exploratory association analyses were strictly restricted to the subset of 34 patients with definitively adjudicated polycythemia vera. The investigators utilized competing-risk methods to evaluate complete hematologic response, disease progression, and toxicity-related treatment discontinuation across a median follow-up duration of 26.5 months.

Under the competing-risk framework, ropeginterferon alfa-2b demonstrated expanding hematologic control over time in patients with definitive polycythemia vera. The cumulative incidence of complete hematologic response reached 43.3 percent at 12 months of follow-up. With extended treatment, this measure increased further, achieving a cumulative incidence of 60.7 percent at 24 months, indicating progressive therapeutic response within the evaluated cohort.

The treatment also led to a substantial and statistically significant reduction in procedural interventions for disease management. Among the patients with definitive polycythemia vera, median phlebotomy requirements fell from three procedures during the pretreatment trimester down to 0.5 procedures during the first treatment trimester. This marked reduction in phlebotomy requirements achieved high statistical significance, with a reported value of P < 0.001.

Safety evaluations across the entire cohort of 42 treated patients revealed that 23 individuals, or 54.8 percent, experienced at least one treatment-emergent adverse event. Overall, six patients, representing 14.3 percent of the treated population, permanently discontinued therapy due to treatment-related toxicity. Based on competing-risk analysis, the cumulative incidence of toxicity-related discontinuation reached 15.9 percent by six months and remained completely unchanged through 24 months of follow-up, indicating that treatment-limiting toxicity was concentrated early during therapy.

Because treatment-limiting adverse events occurred predominantly during the first six months, the authors highlighted the necessity of careful monitoring during treatment initiation and subsequent dose titration. Among responding patients, notable therapeutic adjustments were documented: a de-escalated maintenance regimen was successfully implemented in 12 responders, and a treatment-free interval was sustained in three selected patients. Across the evaluated population, six patients experienced disease progression during follow-up.

Exploratory association analyses evaluated the relationship between neutrophil-to-lymphocyte ratio values and disease progression, though these investigations were limited by the small number of events. Consequently, the analyses yielded potentially unstable estimates that remain susceptible to sparse-data bias and overfitting. Although higher baseline and time-updated neutrophil-to-lymphocyte ratio values were associated with disease progression, within-patient changes did not provide additional prognostic information beyond baseline measurements. The authors underscored that these exploratory analyses do not establish independent prognostic factors or validate serial monitoring, concluding that larger multicenter studies with longer follow-up are needed to confirm the observations.

Subject of Research: Real-world effectiveness and safety of ropeginterferon alfa-2b in polycythemia vera

Article Title: Real-world effectiveness and safety of ropeginterferon alfa-2b in polycythemia vera: a competing-risk analysis

Article References: Thomopoulos, T. P., Bouchla, A., Vryttia, P., Apostolopoulou, C., Spathis, A., Zorba, A., Markaki, I., Karamanou, G., Foukas, P. G., Pappa, V., & Papageorgiou, S. G. (2026). Real-world effectiveness and safety of ropeginterferon alfa-2b in polycythemia vera: a competing-risk analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07362-w

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07362-w

Keywords: ropeginterferon alfa-2b, polycythemia vera, competing-risk analysis, hematologic response, phlebotomy requirements, real-world effectiveness, drug safety, treatment discontinuation, adverse events, neutrophil-to-lymphocyte ratio, disease progression, dose titration, maintenance regimen, treatment-free interval, Annals of Hematology, hematology

News Source: Ophelia Keating. (November 17, 2026). Ropeginterferon Alfa-2b Controls Polycythemia Vera and Cuts Phlebotomy Needs in Practice. Scienmag.

Tags: adverse eventsAnnals of Hematologycompeting-risk analysisdisease progressiondose titrationdrug safetyhematologic responseHematologymaintenance regimenNeutrophil-to-lymphocyte ratiophlebotomy requirementspolycythemia verareal-world effectivenessropeginterferon alfa-2btreatment discontinuationtreatment-free interval
Share12Tweet7Share2ShareShareShare1

Related Posts

South Korea Longevity Gains Driven Increasingly by Shifting Old-Age Mortality

South Korea Longevity Gains Driven Increasingly by Shifting Old-Age Mortality

November 19, 2026
Intraoperative Hypotension Exposure Fell 41 Percent in Major Non-Cardiac Surgeries

Intraoperative Hypotension Exposure Fell 41 Percent in Major Non-Cardiac Surgeries

November 19, 2026

Pasteurella Multocida Type A Outbreak Drives Severe Fatal Pneumonia in Gilts

November 19, 2026

Melanoma Study Identifies Macrophage-Linked cGAS-STING Hub Genes and Therapeutic Candidates

November 19, 2026

POPULAR NEWS

  • Oncology Corridor Assessment Identifies Widespread Therapeutic and Environmental Deficits

    Oncology Corridor Assessment Identifies Widespread Therapeutic and Environmental Deficits

    29 shares
    Share 12 Tweet 7
  • Chamomile Oil and Apigenin Suppress Antibiotic Efflux Pump Genes in Clinical Bacteria

    29 shares
    Share 12 Tweet 7
  • Preoperative Arterial Embolization Shows Mixed Complication Risks in Pancreatic Surgery

    29 shares
    Share 12 Tweet 7
  • Mexican Jaguar Corridors Face Structural Habitat Shifts and Movement Bottlenecks

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Autistic Adolescents Rely on Abstract Prototypes During Category Learning, Study Finds

South Korea Longevity Gains Driven Increasingly by Shifting Old-Age Mortality

Intraoperative Hypotension Exposure Fell 41 Percent in Major Non-Cardiac Surgeries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.